March 26, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce the voting results from the Annual General and Special Meeting of its Shareholders (the “Meeting”) held on Wednesday, March 26, 2025. A total of 40,294,667 common shares were voted at the Meeting, representing 76.00% of Helix’s total issued and outstanding shares.

 

Shareholders voted overwhelmingly in favor of all items of business before the Meeting. The four director nominees listed in Helix’s Management Information Circular (the “Information Circular”) dated January 31, 2025, were re-elected as directors of the Company to hold office for the ensuing year or until their successors are elected or appointed. The detailed results of the vote for each director are set out below:  

 

	Jacek Antas		Jerzy Leszczynski		Janusz Grabski		Malgorzata Laube
	#	%	#	%	#	%	#	%
Votes in Favor	40,291,307	99.99%	40,292,267	99.99%	40,291,467	99.99%	40,292,267	99.99%
Votes Withheld	3,360	0.01%	2,400	0.01%	3,200	0.01%	2,400	0.01%

 

The resolutions to appoint Clearhouse LLP as auditor of Helix BioPharma until the next annual general meeting at remuneration to be determined by the directors, were approved with 99.61% of the votes cast in favor.

 

The resolution regarding the asset transactions contemplated by the asset purchase agreements with Laevoroc Immunology AG and Laevoroc Chemotherapy AG dated November 28, 2024 and November 30, 2024, respectively, each as amended on December 5, 2024, in accordance with the policies of the Toronto Stock Exchange (“TSX”), was approved with 99.61% of the votes cast in favor.

 

The resolution regarding the equity draw-down subscription facility that may provide the Company with access to funds of up to CA$25,000,000 (the “Financing”), as contemplated in the term sheet dated October 15, 2024, between the Company and GEM Yield Bahamas Limited (“GYBL”) and the share subscription agreement (the “Share Subscription Agreement”) to be entered into among the Company, GYBL, GEM Global Yield LLC SCS (“GEM”) and certain holders of unrestricted Common Shares following TSX and shareholder approval, was approved with 99.61% of the votes cast in favor.

 

The resolution regarding the amendment to the articles of the Company to effect a consolidation of the issued and outstanding Common Shares on the basis of a consolidation ratio selected by the Board of Directors of the Company (“the Board”) of up to five (5) pre-consolidation Common Shares for one (1) post-consolidation Common Share, and to authorize the Board to determine the final consolidation ratio at its sole discretion, as more particularly described in the Information Circular, was approved with 99.98% of the votes cast in favor.

The resolution regarding the change of name of the Company to “Aconara Pharma Corp.” or such other name as the Board may determine was approved with 99.60% of the votes cast in favor.

 

The resolution regarding, with or without variation, (i) the approval of all unallocated options, rights and other entitlements under Helix’s Equity Compensation Plan; and (ii) the confirmation and approval of such plan; and (iii) the approval of the granting by Helix of options, rights and other entitlements under such plan for a further three years, was approved with 99.60% of the votes cast in favor.

 

A report on all items of business voted at the Meeting will be filed on SEDAR+ at www.sedarplus.com.

 

About Helix BioPharma Corp.

Helix BioPharma is an oncology company shaping a near future where today’s hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company innovates from strength to tackle cancer’s biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing solid tumors. Its lead candidate, Tumour Defence Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumors, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today’s front-running anti-cancer therapies. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bi-specific ADCs targeting CEACAM6 in discovery.

 

Helix is listed on the TSX under the symbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWB under the symbol “HBP0”. For more information, please visit: https://www.helixbiopharma.com/

 

For more information, please contact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

 

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to L-DOS47. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

 

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.

 

The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company’s annual management’s discussion and analysis for the year ended July 31, 2023 under the heading “Risks and Uncertainties” and Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required.